NCT01142453View on ClinicalTrials.gov

An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

CompletedOBSERVATIONAL
Enrollment

231

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
DRUG

Interferon beta 1a

A dosage of 44 µg interferon beta 1a subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase (depending on the respective preliminary therapy)

All Listed Sponsors
collaborator

Gesellschaft für Therapieforschung mbH

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01142453 - An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients | Biotech Hunter | Biotech Hunter